All I'm saying is under their current policy, being awarded an SBIR Phase 3 will not have much of an impact on the stock. Without an official PR, and being located at the near bottom OTC tier, I don't see it going over .02, if that.
However, AFTC has more than one oar in the water, and anything is possible with their DME products.
I've been in this stock over 4 years, and will be happy to wait another year if that's what it takes.